[治疗较低风险的骨髓分裂综合征]
1CHU de Grenoble, service d'hématologie, CS 10217, 38043 Grenoble cedex 09, France.
Bulletin du cancer
|July 27, 2023
概括
对于低风险的骨髓质疏松症候群 (MDS),红色素形成刺激剂 (ESAs) 能够控制贫血. 由于急性髓性白血病转变风险更高,新疗法对抗ESA的MDS至关重要.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 内部医学 内部医学
背景情况:
- 低风险的骨髓质疏松症候群 (MDS) 主要需要治疗以纠正细胞衰竭.
- 贫血是一种常见的后果,由红色素形成刺激剂 (ESAs) 有效管理.
- 一部分患有低风险MDS的患者对ESA表现出耐药性,需要使用替代治疗策略.
研究的目的:
- 审查ESA在低风险MDS中的疗效和响应预测指标.
- 探索ESA耐药低风险MDS患者的新兴治疗选择.
- 讨论MDS中症状性血小板缺血的管理策略.
主要方法:
- 关于MDS治疗的当前文献的审查.
- 分析影响对ESA反应的因素.
- 识别MDS的新药和治疗方法.
主要成果:
- 在低风险的MDS中,ESA是治疗贫血的基石.
- 确定了ESA反应的预测因素.
- 一些新药,包括luspatercept,lenalidomide,imetelstat和roxadustat,对抗ESA的MDS显示出希望.
- 雄激素治疗和TPO激动剂为血小板缺血提供了选择.
结论:
- 虽然ESA对许多人有效,但抗ESA的MDS需要新的治疗开发.
- 急性髓性白血病 (AML) 转变的风险强调了对抗ESA病例的先进治疗的需要.
- 针对性治疗和支持性护理对于优化低风险MDS患者的结果至关重要.
相关概念视频
Bone Marrow Sampling and Transplants
360
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
360
Differentiation of Common Myeloid Progenitor Cells
3.2K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.2K


